Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Deccan Health CareBOM:542248 -2.89%77 PS Ratio is 0.39 as of Aug. 15, 2026, which is 89% below its 10-year median of 3.62. GuruFocus rates BOM:542248 with a GF Score™ of 77/100 and a GF Value™ of ₹26.14 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 951 Drug Manufacturers companies, Deccan Health Care ranks better than 91.38% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Deccan Health Care's share price is ₹13.09.
Deccan Health Care's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹33.91. Hence, Deccan Health Care's PS Ratio for today is 0.39.
The historical rank and industry rank for Deccan Health Care's PS Ratio or its related term are showing as below:
BOM:542248'
s PS Ratio Range Over the Past 10 Years
Min: 0.22 Med: 3.62 Max: 23.69
Current: 0.39
During the past 11 years, Deccan Health Care's highest PS Ratio was 23.69. The lowest was 0.22. And the median was 3.62.
BOM:542248's PS Ratio is ranked better than 91.38% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs BOM:542248: 0.39
Deccan Health Care Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Deccan Health Care was 14.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -2.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.50% per year.
During the past 11 years, Deccan Health Care's highest 3-Year average Revenue per Share Growth Rate was 45.10% per year. The lowest was -12.40% per year. And the median was 10.45% per year.
Deccan Health Care (BOM:542248) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Deccan Health Care PS Ratio Related Terms
Deccan Health Care PS Ratio Historical Data
* Premium members only.
The historical data trend for Deccan Health Care's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Deccan Health Care's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Deccan Health Care PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Deccan Health Care's PS Ratio distribution charts can be found below:
* The bar in red indicates where Deccan Health Care's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Deccan Health Care's Share Price of today is ₹13.09. Deccan Health Care's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹33.91.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Deccan Health Care (BOM:542248) has a PS Ratio of 0.39 as of Aug. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Deccan Health Care and its competitors. This is 89% below median its historical median of 3.62. Over the past decade, Deccan Health Care's PS Ratio has ranged from 0.22 to 23.69. According to the industry distribution chart, Deccan Health Care ranks #82 out of 951 companies in the Drug Manufacturers industry, placing it in the top 8.6%.
Is Deccan Health Care's PS Ratio too high?
Deccan Health Care's current PS Ratio of 0.39 is 89% below median its 10-year median of 3.62. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 23.69. The Drug Manufacturers industry median PS Ratio is 2.33. Deccan Health Care's value of 0.39 is 83.3% below this industry median. Based on the distribution chart, Deccan Health Care ranks #82 out of 951 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Deccan Health Care has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Deccan Health Care's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Deccan Health Care ranks #82 out of 951 companies for PS Ratio. This places Deccan Health Care in the top 9% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.33. Deccan Health Care's value of 0.39 is 83.3% below this benchmark. Historically, Deccan Health Care's own PS Ratio has ranged from 0.22 to 23.69 over the past decade. While the company's 10-year median is 3.62 vs. the industry median of 2.33, Deccan Health Care has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Deccan Health Care's current PS Ratio of 0.39 is 83.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Deccan Health Care and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Deccan Health Care's current PS Ratio is 0.39, which is 89% below median its own 10-year median of 3.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Deccan Health Care stock overvalued right now?
Based on GuruFocus' analysis, Deccan Health Care (BOM:542248) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹26.14, compared to a current price of ₹13.09 — trading 49.9% below its estimated fair value. The current PS Ratio is 0.39, which is 89% below median its 10-year median of 3.62 and 83.3% below the Drug Manufacturers industry median of 2.33. Deccan Health Care's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Deccan Health Care (BOM:542248), the current PS Ratio is 0.39 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Deccan Health Care (BOM:542248) Overvalued in 2026?
Based on GuruFocus' analysis, Deccan Health Care stock appears to be undervalued.
The current stock price of ₹13.09 is trading 49.9% below its estimated GF Value™ of ₹26.14.
GuruFocus considers Deccan Health Care to be Significantly Undervalued.
Key valuation signals for BOM:542248:
PS Ratio: 0.39 (89% below median its 10-year median of 3.62)
GF Value™: ₹26.14 vs. price of ₹13.09 (49.9% below fair value)
Industry Position: 83.3% below the Drug Manufacturers median (#82 of 951)
No single metric tells the full story. See the BOM:542248 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Deccan Health Care Ltd is into developing, manufacturing, and marketing a broad range of healthcare products, including nutraceutical, cosmeceutical, and ayurveda products (Fast Moving Consumer Health Products). Its products are Nutraceutical Food Products and other supplements and medicines. The company is operating in a single segment of manufacturing of nutraceutical products. The company operates in India as well as exports its products to other countries, and the majority of its revenue comes from India.
77GF Score
Get the complete analysis for BOM:542248
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542248 has been successfully added to your 
